Brandywine Realty Trust
Brandywine Realty Trust Q4 FY2025 earnings call
February 4, 2026 · fiscal period ended 2025-12
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2026-02-04
Management highlights
• 2025 results in line with business plan, strong operating metrics, flight to quality among tenant base. • Wholly-owned core portfolio occupancy and leasing stats. Forward leasing, spec revenue, tenant retention, leasing activity. Capital ratio, mark-to-market. Tour volume growth, conversion rates. • Philadelphia and Pennsylvania suburbs market dynamics. Brandywine's market share. • Liquidity in solid shape, no outstanding line of credit balance, cash on hand. Bond refinancing opportunities. • Recapitalization of development joint ventures, including 3025 and 3151 buyouts, pipeline details. • 2026 business plan focus on earnings growth, operating results, sales program, core portfolio performance, spec revenue, occupancy, mark-to-market, leasing capital, same-store growth.
Segment performance
Wholly-owned core portfolio is 88.3% occupied and 90.4% leased. Forward leasing commencing after year-end increased 26% to 229,000 square feet. Generated near $27.3 million of spec revenue. Tenant retention target ended at 64% vs original range 59%-61%. Leasing activity for the year approximated 1.6 million square feet. During the quarter, 415,000 square feet of leases executed. Capital ratio for the year was 9.5%. GAAP mark-to-market was 4.2%, new leasing mark-to-market 13% (GAAP) and 4% (cash). Tour volume: fourth quarter exceeded third quarter by 13%, exceeded fourth quarter 2024 by 87%. 45% of new leasing in fourth quarter wholly-owned was flight to quality. Annual tour volume 2025 outpaced 2024 by 20% (fiscal number of tours) and 45% (square footage). In Philadelphia, 95% occupied and 97% leased, Commerce Square joint venture 90% leased. Brandywine captured 54% of new leasing in Market West and University City in 2025. Net effective rents in Philadelphia submarkets increased ~20% since 2021. Pennsylvania suburbs 89.4% leased, Radnor 91% leased. Austin 74% occupied. Operating portfolio leasing pipeline 1.5 million square feet. Core portfolio will add 3025 in first quarter and 250 Radnor in second quarter. Spec revenue targeted $17M - $18M. Year-end occupancy projected to improve 120 basis points. GAAP mark-to-market range 5%-7%, cash mark-to-market -2% to 0%. Leasing capital target 12%-13%. Same-store growth GAAP -1% to +1%, cash 0% to 2%.
Guidance
• 2026 FFO guidance range $0.51 - $0.59 per share, midpoint $0.55, 5.8% increase over 2025. • Operating metrics: property-level GAAP NOI $292M, increase of $30M from 2025. 3025 JFK to add $17M. Asset sales and move-outs to cause $7M NOI decrease. Unconsolidated joint ventures contribution to improve from $11M loss in 2025 to $1M income in 2026. ATX developments to improve $9M. G&A expense $36M - $37M, $5.5M below 2025. Total interest expense ~$170M, $30M increase from 2025. Termination and other income $9M - $11M vs $6.6M in 2025. Sales activity $290M, first half focus. Financing activity: refinance 3025 JFK loan, consider extension of credit facility, recapitalize ATX joint ventures in second half. No property acquisitions. First quarter property-level NOI ~$70M, FFO contribution from joint ventures positive $0.5M, G&A $12M, total interest expense ~$42M. Capital plan ~$475M, cash on hand $52M at year-end, net debt to EBITDA 8.4 - 8.8, fixed charge ratio 1.8 - 2.0.
Q&A highlights
Q: Seth Bergey asked about bond refinancing hurdle and share buyback vs debt repurchase.
A: Jerry Sweeney said first course is sales program to improve credit metrics. Primary focus of sales proceeds is to reduce leverage, share buyback optionality when other objectives met.
Q: Anthony Paolone asked about portfolio undervaluation and what to sell.
A: Jerry Sweeney said entire portfolio undervalued. Sale program is company-wide look at marketable assets with 8% average cap rate, focusing on marketable assets now.
Q: Steve Sakwa asked about JV recaps timing.
A: Jerry Sweeney said JV recaps planned for second half of 2026, monitoring leasing progress and market conditions.
Q: Steve Sakwa asked about pipeline color.
A: Jerry Sweeney and George Johnstone said strongest trends in CBD Philadelphia and University City, Radnor and King of Prussia activity, 3151 and One Uptown pipeline.
Q: Upal Rana asked about IBM move-out in Austin and redevelopment.
A: Jerry Sweeney said IBM move-out starting end of first quarter 2026, planning redevelopment of existing building with $30M - $40M cost.
Q: Upal Rana asked about additional dispositions.
A: Jerry Sweeney said $280M - $300M target for 2026, other properties and land holdings queued for sale.
Q: Dylan Burzinski asked about deleveraging and share buybacks.
A: Jerry Sweeney said aim to get to investment-grade leverage, deleveraging through asset sales and NOI growth, considering share buybacks when undervaluation and liquidity allow.
Q: Dylan Burzinski asked about development projects outside Austin.
A: Jerry Sweeney said development projects outside Austin not off sale list, evaluated for refinancing and joint ventures.
Q: Michael Lewis asked about asset sale cap rate and bond proceeds.
A: Jerry Sweeney said average cap rate ~8% for sales, Thomas E. Wirth said proceeds to be used to delever and buy back bonds.
Q: Michael Lewis asked about recap and M&A.
A: Jerry Sweeney said Board and management review strategic direction, focus on deleveraging, stabilizing developments, and recycling assets.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | — | — | — | — |
| Revenue | — | — | — | — |
Transcript
February 4, 2026Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.